Aqtual, Inc., a rising star in precision health, has successfully closed a $31 million Series B round to scale its groundbreaking molecular measurement platform aimed at autoimmune and inflammatory diseases. Led by Diana Abdueva, the company is rapidly emerging as a category leader in real-time immune monitoring - a domain that’s gaining massive traction across biotech and personalized medicine.

The funding round saw strong support from a strategic group of forward-looking investors, including Bold Capital, BOLD Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, and Yu Galaxy, among others. This milestone not only signals confidence in Aqtual’s platform but also reflects the growing appetite for AI-powered immunology solutions in the biotech ecosystem.

---

Transforming Immune Health Through Precision and Speed

Aqtual is developing an advanced platform that enables real-time monitoring of immune system activity at the molecular level. This has the potential to revolutionize how diseases like rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease are diagnosed, tracked, and treated.

Traditional diagnostic tools often provide delayed, static snapshots of immune behavior. Aqtual’s innovation allows clinicians to dynamically observe how a patient’s immune system is reacting to therapies or disease states, paving the way for more precise, timely, and tailored interventions.

By delivering actionable biomarkers in real time, Aqtual is essentially turning immunology into a live feedback system, something long absent from chronic inflammatory care.

---

One of the most overlooked paths to product-market fit in healthtech is solving for temporal asymmetry - the lag between what’s happening in the body and when the system detects it. Aqtual eliminates this lag.

If you’re building in a regulated or data-rich industry, the key is this: make the invisible measurable - and the measurable fast. Speed doesn’t just improve outcomes; it compounds user trust. Whether in health, logistics, or finance, when your platform reduces diagnostic delay, you’re not just enabling decisions - you’re redefining them.

---

Why Autoimmune Disorders Demand Innovation Now

The global burden of autoimmune diseases is staggering:

• Over 50 million Americans suffer from autoimmune conditions, with that number growing annually.
  
• Globally, the autoimmune disease diagnostics market is projected to hit $9.3 billion by 2030, growing at a CAGR of 7.5%.
  
• Rheumatoid arthritis alone affects nearly 1 in 100 people worldwide, and delays in treatment can lead to irreversible joint damage and systemic complications.
  

Despite this, the standard of care often relies on broad immunosuppressants and delayed clinical markers. Aqtual’s real-time measurement solution offers a paradigm shift - enabling personalized dosing, early relapse detection, and faster therapeutic feedback loops.

---

A Perfect Storm of Market Timing and Tech Maturity

Aqtual’s Series B raise lands at a time when several trends are converging:

1. Precision medicine is becoming standard care – With the rise of gene therapies and biologics, doctors need better data to make exact treatment decisions.
   
2. AI and cloud-based platforms are accelerating biological analysis – Tools that used to take weeks now operate in near-real time.
   
3. Venture capital in immunology is heating up – Over $8.4 billion was invested globally in immunology-related startups in 2024 alone.
   

These forces position Aqtual to capitalize on what many see as the next frontier of personalized care - immune intelligence.

---

Meet the Strategic Backers

The company’s investor lineup reads like a who’s-who of mission-driven capital:

• Bold Capital and BOLD Longevity Growth Fund bring deep expertise in healthspan and deep tech biology.
  
• Genoa Ventures has a track record of backing tools that shift biology into the digital era.
  
• Manta Ray Ventures and Yu Galaxy are known for backing scalable science with global impact.
  

These backers not only bring capital, but also key relationships in health systems, pharma, and bioinformatics - critical for scaling in a domain where partnerships drive adoption.

---

What’s Next for Aqtual, Inc.?

With $31M in fresh capital, Aqtual plans to:

• Expand clinical collaborations with major hospitals and academic medical centers.
  
• Accelerate R&D to deepen its platform’s disease-specific diagnostic precision.
  
• Scale commercial operations, especially in North America and Europe.
  
• Launch new data-sharing APIs for pharmaceutical researchers to integrate immune metrics into drug trials.
  
• Continue building its cloud-based molecular insight dashboard for physicians and researchers.
  

The company’s ultimate goal is to become the default immune health operating system - a new standard that enables real-time, adaptive care across dozens of inflammatory conditions.

---

Conclusion: The Future of Autoimmune Care is Real-Time

Aqtual is delivering something the market has long needed but never had: a living window into the immune system. By making immune activity visible in real-time, the company is poised to redefine how millions are diagnosed, treated, and monitored.

As the precision medicine revolution continues to unfold, and as autoimmune diseases rise globally, Aqtual’s platform offers both timeliness and truth - two things healthcare can never have enough of.

With this Series B raise, a world-class investor roster, and a product built at the intersection of biotech and AI, Aqtual, Inc. is well on its way to becoming a foundational player in the immune intelligence era.

---